Evidence map›Paper›PMID 39362963›Full record

ArticleScientific reports2024

Bioinformatic analysis of molecular characteristics and oncogenic features of CARD14 in human cancer.

Daniil Bespalov, Dayana Pino, Sònia Vidal-Guirao, Júlia Franquesa, Daniel Lopez-Ramajo, Ingrid Filgaira, Li Wan, Paul A O'Sullivan, Steven C Ley, Sonia Vanina Forcales and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniil Bespalov *Immunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Dayana Pino *Immunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Sònia Vidal-GuiraoImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Júlia FranquesaImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Daniel Lopez-RamajoImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Ingrid FilgairaImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Li WanKey Laboratory of Immune Response and Immunotherapy, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, 190 Kuaiyuan Avenue, Guangzhou, 510530, China.
Paul A O'SullivanMRC Centre for Molecular Bacteriology & Infection, Imperial College London, London, SW7 2AZ, UK.
Steven C LeyInstitute of Immunity & Transplantation, Royal Free Hospital, University College London, London, NW3 2PP, UK.
Sonia Vanina ForcalesImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Juan José RojasImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Mercè Izquierdo-SerraNeurohysiology Group, Department of Biomedicine, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, 08036, Spain.
Concepció SolerImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain.
Joan ManilsImmunology Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona, Barcelona, 08007, Spain. joanmanils@ub.edu.ORCID 0000-0001-8429-1295

Funding

Ministerio de Ciencia e Innovación PID2020-114477RB-I00Ministerio de Ciencia e Innovación PID2021-126249OA-I00Ministerio de Ciencia e Innovación PID2021-127724OA-100
6 · The paper itself

Abstract

Aberrant caspase recruitment domain family member 14 (CARD14) signaling has been strongly associated with inflammatory skin conditions. CARD14 acts as a scaffold protein, ultimately activating the transcription factor NF-KB. Although primarily studied in the context of inflammation, recent research has suggested its potential implications in tumorigenesis. In this study, we gathered The Cancer Genome Atlas (TCGA) tumor data to gauge the involvement of CARD14 in cancer, including genetic alterations, expression patterns, survival correlations, immune cell infiltration and functional interactions across diverse cancer types. We found heightened CARD14 expression in most tumors and there was a significant correlation between CARD14 expression and the prognosis of patients for certain tumors. For instance, patients with higher CARD14 expression had a better prognosis in sarcoma, lung, cervix and head and neck cancers. Moreover, CARD14 expression positively correlated with neutrophil infiltration in most of the cancer types analyzed. Finally, enrichment analysis showed that epithelial development and differentiation pathways were involved in the functional mechanism of CARD14. Our results show that CARD14 may have the potential to become a prognostic biomarker in several cancers, hence, further prospective studies will be required for its validation.

Indexed as

CARD Signaling Adaptor ProteinsComputational BiologyNeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticGuanylate CyclaseHumansMembrane ProteinsPrognosisBiomarkers, TumorCARD14 protein, humanCARD Signaling Adaptor ProteinsGuanylate CyclaseMembrane ProteinsCancerCARD14InflammationPrognosisTCGA

Identifiers

PMID39362963
PMCPMC11452207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.